PMID- 33022902
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 23
DP  - 2020 Dec
TI  - Impact of tumor volume enlargement after induction chemotherapy on subsequent 
      radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity-score 
      matching analysis.
PG  - 8832-8843
LID - 10.1002/cam4.3494 [doi]
AB  - A small proportion of nasopharyngeal carcinoma (NPC) patients show resistance to 
      induction chemotherapy (IC). This study sought to investigate the impact of tumor 
      volume enlargement after IC on the dosimetric parameters of subsequent 
      radiotherapy. The records of a total of 240 locally advanced NPC patients who 
      received IC followed by concurrent chemoradiotherapy were retrospectively 
      reviewed. Patients with a tumor volume enlargement of >/=10% and patients with a 
      tumor volume reduction of >/=10% after induction chemotherapy were classified as 
      the enlargement group and the control group, respectively. The dosimetric 
      parameters of the planning target volumes (PTVs) and the organs at risk (OARs) 
      were compared between the matched groups after propensity score matching (PSM). 
      For the gross tumor volume of nasopharynx (GTVnx), 21 patients and 127 patients 
      were classified as the enlargement group and the control group, respectively. 
      After matching, 20 sub-pairs of 40 patients were generated in the post-PSM 
      cohort. The GTVnx enlargement group exhibited no significant disadvantages in all 
      of the dosimetric parameters, except in the planning organ-at-risk volume (PRV) 
      of contralateral lens (Dmax, 722 cGy vs. 634 cGy, p = 0.041). For the gross tumor 
      volume of lymph nodes (GTVnd), 44 patients and 144 patients were classified as 
      the enlargement group and the control group, respectively. After matching, 39 
      sub-pairs of 78 patients were generated in the post-PSM cohort. The GTVnd 
      enlargement group exhibited no significant disadvantages in all of the dosimetric 
      parameters. Univariate and multivariate analyses showed that the enlargement of 
      GTVnx and the enlargement of GTVnd were not independently associated with any of 
      the dosimetric parameters. A tumor volume enlargement of >/=10% in GTVnx or GTVnd 
      after induction chemotherapy has no significant impact on the dosimetric 
      parameters of subsequent radiotherapy in locally advanced NPC.
CI  - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Li, Shan
AU  - Li S
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      Hunan Province, China.
FAU - Shen, Liangfang
AU  - Shen L
AUID- ORCID: 0000-0001-9474-6329
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      Hunan Province, China.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
SB  - IM
MH  - Humans
MH  - *Induction Chemotherapy/adverse effects
MH  - Nasopharyngeal Carcinoma/pathology/*therapy
MH  - Nasopharyngeal Neoplasms/pathology/*therapy
MH  - Propensity Score
MH  - Radiation Dosage
MH  - Radiotherapy, Adjuvant
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - Tumor Burden
PMC - PMC7724294
OTO - NOTNLM
OT  - dosimetry
OT  - induction chemotherapy
OT  - nasopharyngeal carcinoma
OT  - propensity score matching
OT  - tumor volume
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/10/07 06:00
MHDA- 2021/07/22 06:00
PMCR- 2020/10/06
CRDT- 2020/10/06 20:20
PHST- 2020/03/10 00:00 [received]
PHST- 2020/09/07 00:00 [revised]
PHST- 2020/09/12 00:00 [accepted]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/10/06 20:20 [entrez]
PHST- 2020/10/06 00:00 [pmc-release]
AID - CAM43494 [pii]
AID - 10.1002/cam4.3494 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Dec;9(23):8832-8843. doi: 10.1002/cam4.3494. Epub 2020 Oct 6.